Clinical Research Coordinator I/II
About the job
- Knowledge of clinical research practices, regulations, and terminology, including Food and Drug Administration, International Council for Harmonisation, Good Clinical Practice, Health Insurance Portability and Accountability Act, and Institutional Review Board requirements.
- Experience supporting clinical research activities such as participant recruitment, informed consent, data collection, and regulatory documentation.
- Ability to ensure protocol compliance, data quality, and participant safety.
- Familiarity with medical terminology and basic patient care procedures.
- Ability to maintain confidentiality of participant data and study records.
- Medical Assistant, Phlebotomist, and Medical Assistant–Registered licensure is required, though it may be obtained after hire.
- Clinical Research Coordinator I requires a minimum of one year of full-time experience in clinical research, healthcare, or a related field.
- Clinical Research Coordinator II requires a minimum of two years of clinical research experience with direct study coordination responsibilities.
- Clinical Research Coordinator II requires the ability to independently manage studies or complex study components.
- Clinical Research Coordinator II requires experience with more complex protocols, such as multiple sites, investigational products, or early-phase trials.
- Clinical Research Coordinator II requires strong working knowledge of regulatory processes and compliance requirements.
- Coordinate and conduct clinical research study visits, including scheduling, participant interaction, and protocol-required procedures.
- Recruit, screen, and enroll study participants, including obtaining informed consent and collecting medical history.
- Collect and document clinical data, including vital signs, questionnaires, and study-related assessments.
- Perform or support specimen collection and processing, including blood draws and centrifugation, in accordance with protocol and licensure.
- Maintain accurate and complete source documentation and case report forms in compliance with study requirements.
- Support regulatory activities, including maintaining study files, preparing submissions, and ensuring audit readiness.
- Ensure compliance with study protocols, institutional policies, and applicable regulations, including Good Clinical Practice, Food and Drug Administration, and Institutional Review Board requirements.
- Coordinate participant care activities such as appointment scheduling, follow-up, and communication.
- Prepare for and support study monitoring visits and audits.
- Participate in quality control and process improvement efforts.
- Clinical Research Coordinator I supports study start-up activities and day-to-day coordination under guidance.
- Clinical Research Coordinator I assists with recruitment strategies and participant tracking.
- Clinical Research Coordinator I learns and applies clinical research regulations, processes, and protocol requirements.
- Clinical Research Coordinator I escalates issues related to protocol deviations, participant safety, or data quality.
- Clinical Research Coordinator II independently manages one or more studies or complex study components.
- Clinical Research Coordinator II leads study start-up activities, including protocol implementation and site preparation.
- Clinical Research Coordinator II develops and implements recruitment and retention strategies.
- Clinical Research Coordinator II ensures high-level oversight of data quality, regulatory compliance, and study timelines.
- Clinical Research Coordinator II troubleshoots operational challenges and implements process improvements.
- Experience with clinical equipment such as a centrifuge and electrocardiogram.
- Experience working with autoimmune disease or immunology-focused studies.
- Prior experience with investigational product or test article handling.
- Experience preparing for audits or monitoring visits.
- Interest in process improvement and clinical research operations.
- Clinical Research Coordinator II may provide guidance or informal mentorship to junior staff.
- Clinical Research Coordinator II may train or provide guidance to junior staff or new team members.
About the company
Preparing summary.
Company Size
201-500
Company Stage
Grant
Total Funding
$22M
Headquarters
Seattle, Washington
Founded
1956
Get referred to Benaroya Research Institute
See people who can refer or advise you
Simplify's Take
What believers are saying
- BRI won 16.2 million dollars across 18 grants in first-half 2026.
- The August 2026 pancreas cancer trial launch broadens BRI beyond autoimmune disease.
- POLARIS dosing began in 2026, creating human data for BRI-designed T1D therapies.
What critics are saying
- BRI still depends on NIH grants and sponsored research, totaling 18 awards in 2026.
- GNTI-122’s POLARIS trial started January 2026; safety failure would damage BRI’s engineered-Treg story.
- Partner concentration with GentiBio and VMFH makes one program setback cascade across translational credibility.
What makes Benaroya Research Institute unique
- BRI pairs deep human immunology with Virginia Mason clinical access in Seattle.
- Its 2026 hiring of Edward Irvine expands protein-engineering and AI antibody design.
- BRI spans autoimmune diseases broadly, not single-disease programs, accelerating shared discoveries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Spending Accounts: health care, dependent care, commuter
Disability Insurance
Life and AD&D Insurance
Paid Holidays
Paid Vacation
Paid Sick Leave
Employee Assistance Program
Tuition Reimbursement
Commuter Benefits
Wellness Program
Voluntary Benefits
Growth & Insights and Company News
6 month growth
3%1 year growth
3%2 year growth
3%Press releases. Seattle, WA - Aug 3, 2026 Benaroya Research Institute appoints new principal investigator Edward Irvine, PhD. Benaroya Research Institute (BRI), a world leader in human immunology research, welcomed the addition of Edward Irvine, PhD, as principal investigator and assistant member in the Center for Systems Immunology. "We are very excited to welcome Dr. Irvine," said Jane Buckner, MD, president of BRI. "His research brings new and innovative expertise to BRI. We look forward to seeing how his background in protein engineering and AI helps advance our vision of a healthy immune system for all." The Irvine Lab will combine protein engineering, AI and immunology to study how antibodies communicate with immune cells. A major focus of the lab will be the antibody Fc domain, which helps determine how the immune system responds after an antibody recognizes its target. By uncovering the rules that connect Fc sequence and structure to immune function, the lab aims to design antibodies that direct immune responses with greater precision and support the development of therapies that restore and protect immune health. "I came to BRI because it brings together outstanding scientists and clinicians whose expertise spans many areas of immunology. That creates real opportunities to think creatively about where engineered antibodies could have the greatest impact. I was also drawn to how boldly BRI thinks about what is possible for patients. It truly is an inspiring place to launch a new research program, and I'm excited to contribute," said Dr. Irvine. Prior to joining BRI, Dr. Irvine completed a postdoctoral research fellowship with the Laboratory for Systems and Synthetic Immunology led by Sai Reddy, PhD, at ETH Zurich in Switzerland. During his fellowship, he used protein engineering and AI to develop novel platforms to predict and engineer immune function. Dr. Irvine holds a doctorate in biological sciences in public health with a concentration in immunology and infectious diseases from Harvard University. About Benaroya Research Institute. Benaroya Research Institute (BRI) is a world leader in human immune system research, working to advance the science that will predict, prevent, reverse and cure immune system diseases like allergies, asthma, cancer and autoimmune diseases. BRI accelerates discovery through laboratory breakthroughs in immunology that are then translated to clinical therapies. Benaroya Research Institute believe that a breakthrough in one immune system disease can lead to progress against them all, and work tirelessly toward its vision of a healthy immune system for everyone. BRI is an independent nonprofit research institute affiliated with Virginia Mason Franciscan Health and based in Seattle.
Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Cotter. (Dave Cotter Photo)— Dave Cotter, a longtime Seattle tech leader who sold a startup to Nordstrom and most recently led product at Leafly, launched a new advisory firm called D3 Advisors.“After 30+ years in the operational trenches, I’m now focusing on advising and consulting with startup founders, CEOs, and VC’s, helping them turn great ideas into great companies,” Cotter wrote in a blog post.Cotter was chief product officer at Seattle-based cannabis data and marketplace company Leafly for more than three years before departing in January 2023. He previously co-founded an e-commerce message startup called MessageYes that was acquired by Nordstrom in 2018.Cotter also has exec experience at Amazon, Zulily, SquareHub, and RealNetworks. He’s currently board chair at the Washington Technology Industry Association, and serves on the board of the Technology Alliance.— Johanna Faries, former GM of Call of Duty at Activision, was named president of Blizzard Entertainment. The new role comes as Microsoft just announced a 9% layoff affecting nearly 2,000 employees in its gaming division, three months after the tech giant completed its $69 billion acquisition of Blizzard parent company Activision Blizzard
Zura Bio enters into sponsored Research agreement with Benaroya Research Institute.
Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Adams. (Adaptive Photo)— Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing.Adams joined the Seattle-based biotech giant more than three years ago. The filing stated that “his service is being terminated by May 2023.”His role will be absorbed by Adaptive’s current president, Julie Rubinstein.“Mark Adams has been instrumental in scaling Adaptive’s operations over the past several years, including putting in place world-class technology and operations leaders,” Adaptive said in a statement to GeekWire. “He is an incredible leader and cultural champion, and we are grateful for his contributions to Adaptive.”Adams was previously managing director of healthcare advanced analytics at SVB Securities and was a principal at Booz Allen Hamilton. He was first hired by Adaptive as chief technology officer.Rubinstein joined Adaptive in 2011 as senior vice president of corporate and business development and became president seven years later
Researchers at Benaroya Research Institute (BRI) and the University of Washington published findings today in the Journal of Experimental Medicine that illustrate a novel mechanism for regulatory T cells’ (Tregs) role in maintaining balance in a healthy immune system.